View in EDS HTML Full Text PDF Full Text

Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis.

Saved in:
Bibliographic Details
Title: Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis.
Authors: Hu, Ke1 (AUTHOR), Jiang, Pin2 (AUTHOR), Hu, Jiaxin3 (AUTHOR), Song, Bing4 (AUTHOR), Hou, Ya5 (AUTHOR), Zhao, Jinxuan5 (AUTHOR) njuzhaojinxuan@163.com, Chen, Haiting4 (AUTHOR) cht141230004@163.com, Xie, Jun1,4 (AUTHOR) xiejun@ahmu.edu.cn
Source: Journal of Bioenergetics & Biomembranes. Aug2024, Vol. 56 Issue 4, p361-371. 11p.
Subjects: Myocardial injury, Dapagliflozin, Sodium-glucose cotransporter 2 inhibitors, Treatment effectiveness, Iron metabolism
Abstract: Septic cardiomyopathy is a severe cardiovascular disease with a poor prognosis. Previous studies have reported the involvement of ferroptosis in the pathogenesis of septic cardiomyopathy. SGLT2 inhibitors such as dapagliflozin have been demonstrated to improve ischemia–reperfusion injury by alleviating ferroptosis in cardiomyocyte. However, the role of dapagliflozin in sepsis remains unclear. Therefore, our study aims to investigate the therapeutic effects of dapagliflozin on LPS-induced septic cardiomyopathy. Our results indicate that dapagliflozin improved cardiac function in septic cardiomyopathy experimental mice. Mechanistically, dapagliflozin works by inhibiting the translation of key proteins involved in ferroptosis, such as GPX4, FTH1, and SLC7A11. It also reduces the transcription of lipid peroxidation-related mRNAs, including PTGS2 and ACSL4, as well as iron metabolism genes TFRC and HMOX1. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Bioenergetics & Biomembranes is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: egs
DbLabel: Engineering Source
An: 178209685
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Hu%2C+Ke%22">Hu, Ke</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jiang%2C+Pin%22">Jiang, Pin</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hu%2C+Jiaxin%22">Hu, Jiaxin</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Song%2C+Bing%22">Song, Bing</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hou%2C+Ya%22">Hou, Ya</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhao%2C+Jinxuan%22">Zhao, Jinxuan</searchLink><relatesTo>5</relatesTo> (AUTHOR)<i> njuzhaojinxuan@163.com</i><br /><searchLink fieldCode="AR" term="%22Chen%2C+Haiting%22">Chen, Haiting</searchLink><relatesTo>4</relatesTo> (AUTHOR)<i> cht141230004@163.com</i><br /><searchLink fieldCode="AR" term="%22Xie%2C+Jun%22">Xie, Jun</searchLink><relatesTo>1,4</relatesTo> (AUTHOR)<i> xiejun@ahmu.edu.cn</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Journal+of+Bioenergetics+%26+Biomembranes%22">Journal of Bioenergetics & Biomembranes</searchLink>. Aug2024, Vol. 56 Issue 4, p361-371. 11p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Myocardial+injury%22">Myocardial injury</searchLink><br /><searchLink fieldCode="DE" term="%22Dapagliflozin%22">Dapagliflozin</searchLink><br /><searchLink fieldCode="DE" term="%22Sodium-glucose+cotransporter+2+inhibitors%22">Sodium-glucose cotransporter 2 inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Iron+metabolism%22">Iron metabolism</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Septic cardiomyopathy is a severe cardiovascular disease with a poor prognosis. Previous studies have reported the involvement of ferroptosis in the pathogenesis of septic cardiomyopathy. SGLT2 inhibitors such as dapagliflozin have been demonstrated to improve ischemia–reperfusion injury by alleviating ferroptosis in cardiomyocyte. However, the role of dapagliflozin in sepsis remains unclear. Therefore, our study aims to investigate the therapeutic effects of dapagliflozin on LPS-induced septic cardiomyopathy. Our results indicate that dapagliflozin improved cardiac function in septic cardiomyopathy experimental mice. Mechanistically, dapagliflozin works by inhibiting the translation of key proteins involved in ferroptosis, such as GPX4, FTH1, and SLC7A11. It also reduces the transcription of lipid peroxidation-related mRNAs, including PTGS2 and ACSL4, as well as iron metabolism genes TFRC and HMOX1. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Journal of Bioenergetics & Biomembranes is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=178209685
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10863-024-10020-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 361
    Subjects:
      – SubjectFull: Myocardial injury
        Type: general
      – SubjectFull: Dapagliflozin
        Type: general
      – SubjectFull: Sodium-glucose cotransporter 2 inhibitors
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Iron metabolism
        Type: general
    Titles:
      – TitleFull: Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hu, Ke
      – PersonEntity:
          Name:
            NameFull: Jiang, Pin
      – PersonEntity:
          Name:
            NameFull: Hu, Jiaxin
      – PersonEntity:
          Name:
            NameFull: Song, Bing
      – PersonEntity:
          Name:
            NameFull: Hou, Ya
      – PersonEntity:
          Name:
            NameFull: Zhao, Jinxuan
      – PersonEntity:
          Name:
            NameFull: Chen, Haiting
      – PersonEntity:
          Name:
            NameFull: Xie, Jun
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: Aug2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 0145479X
          Numbering:
            – Type: volume
              Value: 56
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Journal of Bioenergetics & Biomembranes
              Type: main
ResultId 1